The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 1 week back · Material filings: 447 · All filings: 661

Material

Friday 13 Nov76 filings read · 31 material

  • 10-KFiled 13 Nov 2026Industrials

    Adient plcADNT

    Annual report (10-K), FY2026

    Fundamentals: Watch 35 → Watch 41Value: Very strong 84 → Very strong 95

    The reported numbers improved.

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026All industries

    CNO Financial Group, Inc.CNO

    8-K · Items 1.01, 3.03 — Material agreement

    CNO Financial amended its Section 382 Rights Agreement, extending the expiration date to November 2029 and updating purchase price and preferred stock terms. The plan protects tax net operating loss carryforwards by deterring ownership stakes of 4.99% or more without board approval.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 13 Nov 2026All industries

    CareTrust REIT, Inc.CTRE

    8-K · Items 1.01, 8.01 — Material agreement

    CareTrust REIT entered into forward sale agreements for 19.55M shares at $36/share initial price. Underwriters borrowed and sold shares short. Company faces potential forced settlement and shareholder dilution if acceleration events occur.

    News flow: Balanced 54 → Balanced 51Recognition: Balanced 61 → Balanced 64Gap Very high · 50 → Medium · 20

    The filings read less positively.

    The gap narrowed — attention is catching up.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 13 Nov 2026All industries

    Contango Silver & Gold Inc.CTGO

    8-K · Item 1.01 — Material agreement

    Contango Silver & Gold entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald and co-agents, authorizing up to $75M in at-the-market common stock offerings. No shares have been sold; the company is not obligated to sell.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 13 Nov 2026Biotech

    Inhibrx Biosciences, Inc.INBX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 39 → High · 27

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 13 Nov 2026All industries

    Lightwave Logic, Inc.LWLG

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Watch 32 → Watch 26

    The shares became dearer on AIR's value read.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 13 Nov 2026Biotech

    Nektar TherapeuticsNKTR

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Medium · 15 → High · 26

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026Biotech

    Jade Biosciences, Inc.JBIO

    8-K · Item 2.02 — Results of operations

    Jade Biosciences advanced multiple clinical programs ahead of schedule. JADE101 Phase 3 trial (EVERGREEN) initiating Q4 2026; JADE301 Phase 1 expected Q4 2026. Cash runway extended to Q4 2028 ($475.7M). Multiple clinical catalysts expected in 2027.

    Gap Very high · 79 → Very high · 83

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 13 Nov 2026All industries

    QXO, Inc.QXO

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Balanced 62 → Strong 74

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 13 Nov 2026Industrials

    Enovix CorpENVX

    Quarterly report (10-Q), period ending 4 Oct 2026

    Gap High · 32 → High · 40

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026All industries

    SBC Medical Group Holdings IncSBC

    8-K · Item 2.02 — Results of operations

    Q3 2026: Revenue +35% YoY to $59M, operating income +66% to $26M, net income +22% to $16M. Adjusted EBITDA +66% to $28M with 47% margin. Clinic network expanded 36 locations to 293; patient visits +9% YoY.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 13 Nov 2026All industries

    Aaon, Inc.AAON

    8-K · Item 1.01 — Material agreement

    AAON refinanced and expanded its senior credit facility, increasing total borrowing capacity from $600M to $1.2B (including accordion), extending maturity to 2031, and adding a $100M supply chain financing program to enhance liquidity and support growth.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 13 Nov 2026Biotech

    Jade Biosciences, Inc.JBIO

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Very high · 79 → Very high · 83

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 13 Nov 2026Banks

    Enova International, Inc.ENVA

    8-K · Items 1.01, 2.03 — Material agreement

    Enova's subsidiary ODAS IV issued $500.3M in fixed-rate asset-backed notes (Series 2026-2) secured by small business loans. Proceeds used to purchase loans from OnDeck subsidiary. Seventh series issued under existing securitization program with weighted average coupon of 6.58%.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 13 Nov 2026All industries

    Realloys Inc.ALOY

    8-K · Item 2.02 — Results of operations

    REalloys executed non-binding term sheet with U.S. Army for heavy rare earth processing facility at Tooele Army Depot; advanced metallization and processing programs targeting North American rare earth metal production beginning 2027; maintains $116.2M cash, virtually debt-free.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026Software / SaaS

    Science Applications International CorpSAIC

    8-K · Items 1.01, 2.03 — Material agreement

    SAIC closed a $500M private offering of 6.750% Senior Notes due 2034, netting ~$493M after fees. Proceeds used to redeem all outstanding 4.875% Senior Notes due 2028, with remainder for general corporate purposes.

    Value: Balanced 50 → Balanced 55

    The shares became cheaper on AIR's value read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 13 Nov 2026All industries

    Contango Silver & Gold Inc.CTGO

    8-K · Item 2.02 — Results of operations

    Q3-2026 results show significant operational headwinds: gold production down 56% YoY due to mine pit transition and mill processing delays; net loss of $23.0M vs. prior-year loss of $5.4M; cash position declined to $56.6M from $64.8M year-end.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 13 Nov 2026Industrials

    Trimas CorpTRS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 43 → High · 40

    The gap narrowed — attention is catching up.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 13 Nov 2026All industries

    XMax Inc.XMAX

    Quarterly report (10-Q), period ending 30 Sep 2026

    News flow: Balanced 50 → Balanced 47

    The filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 13 Nov 2026Biotech

    Inhibrx Biosciences, Inc.INBX

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show $38.7M net loss (vs. $35.3M prior year), increased debt to $275M, and negative stockholders' equity of $85.9M. Offset by $2M Pfizer license revenue, R&D cost reduction, and advancing clinical milestones for two programs.

    Gap High · 39 → High · 27

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material

Thursday 12 Nov175 filings read · 119 material

  • 8-KFiled 12 Nov 2026Industrials

    Heartflow, Inc.HTFL

    8-K · Item 2.02 — Results of operations

    Heartflow reported Q3 2026 revenue of $72.9M (+57% YoY), beating expectations with 83.6% gross margin. Company raised full-year 2026 guidance to $262–264M (+49–50% growth) from prior $246–250M, citing accelerating U.S. revenue, expanding installed base, and strong Plaque Analysis adoption.

    Recognition: Strong 72 → Strong 68Gap Low · 5 → Medium · 13

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Transcontinental Realty Investors IncTCI

    8-K · Item 2.02 — Results of operations

    Q3 2026 net loss of $0.1M ($0.02/share) vs. prior-year net income of $0.7M ($0.08/share). Revenue up 8% but net operating loss doubled to $2.4M due to $1.4M increase in lease-up property expenses. Interest income declined $0.7M.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Altimmune, Inc.ALT

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 41 → Very high · 51

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Industrials

    Nextnav Inc.NN

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 6 → Medium · 19

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Prime Medicine, Inc.PRME

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    QXO, Inc.QXO

    8-K · Item 2.02 — Results of operations

    Value: Balanced 62 → Strong 71

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Crescent Biopharma, Inc.CBIO

    8-K · Item 2.02 — Results of operations

    Crescent Biopharma reported Q3 2026 results with significant clinical progress: completed dose escalation in Phase 1/2 ASCEND trial (125+ patients dosed), initiated CR-002 Phase 1/2 APOLLO trial, and achieved 9 IND clearances with partner Kelun-Biotech. Multiple data readouts expected in 2027.

    Recognition: Watch 33 → Watch 30Gap Very high · 77 → Very high · 83

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Industrials

    YETI Holdings, Inc.YETI

    Quarterly report (10-Q), period ending 3 Oct 2026

    Recognition: Balanced 52 → Balanced 45Value: Balanced 55 → Strong 69Gap Low · 4 → Low · 0

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The gap closed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Absci CorpABSI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 61 → Balanced 56Gap Medium · 18 → High · 37

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 12 Nov 2026All industries

    Aveanna Healthcare Holdings, Inc.AVAH

    Quarterly report (10-Q), period ending 3 Oct 2026

    Recognition: Balanced 57 → Balanced 54Value: Weak 16 → Weak 20Gap Medium · 18 → High · 30

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 12 Nov 2026Industrials

    National Vision Holdings, Inc.EYE

    Quarterly report (10-Q), period ending 3 Oct 2026

    Recognition: Watch 37 → Watch 44Gap Medium · 10 → Medium · 22

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Fermi Inc.FRMI

    8-K · Item 2.02 — Results of operations

    Fermi secured ~$200M upfront commitment from investment-grade hyperscaler for 600 MW at Project Matador, with additional $90M materials agreement pending. Demonstrates commercial traction and de-risks project funding.

    Gap Very high · 85 → Very high · 88

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Biotech

    SELLAS Life Sciences Group, Inc.SLS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 39 → Watch 32Gap High · 28 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Kodiak Sciences Inc.KOD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 5 → Medium · 12

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Nektar TherapeuticsNKTR

    8-K · Item 2.02 — Results of operations

    Nektar advanced rezpegaldesleukin into Phase 3 development across atopic dermatitis and alopecia areata with all three ZENITH AD trials initiated and ZENITH AA on track for December start. Cash position strengthened to $952.9M from $245.8M year-end 2025.

    Gap Medium · 15 → High · 26

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    NeuroPace IncNPCE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $23.1M missed expectations with only 1% RNS growth. Full-year guidance slashed from $99.5–$101.5M to $91–$92M. CEO cited account-level disruptions and field organization changes. Net loss improved to $3.3M from $4.9M YoY, but trajectory remains concerning.

    Gap Low · 6 → Low · 0

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026All industries

    Accelerant HoldingsARX

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 63 → Balanced 48

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Semiconductors

    T1 Energy Inc.TE

    8-K · Item 2.02 — Results of operations

    T1 Energy signed 1.58GW new offtake contracts post-Section 232 proclamation, raised 2027 production guidance to 5.3GW (sold out), and advanced G2_Austin financing negotiations. Q3 net loss of $34.7M reflects intentional inventory build for 2027 deliveries.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Taysha Gene Therapies, Inc.TSHA

    8-K · Item 2.02 — Results of operations

    Taysha reports Q3 2026 results with strong TSHA-102 safety data (33 patients, no severe SAEs/DLTs), completed BLA-enabling manufacturing campaign meeting specifications, and expects pivotal trial interim data and FDA feedback in H1 2027.

    Gap Medium · 23 → High · 33

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Corteva, Inc.CTVA

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show 9% organic sales decline and 17% EBITDA decline. Brazil market significantly weaker than anticipated due to farmer liquidity constraints and pricing pressure. Full-year guidance reduced; EBITDA now $1.1–1.125B (vs. prior guidance), EPS $0.76–$0.80.

    Recognition: Very strong 80 → Strong 73

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Industrials

    National Vision Holdings, Inc.EYE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 4.8% to $510.5M with adjusted operating margin expanding 320 bps to 7.3%. Adjusted diluted EPS more than doubled to $0.30 from $0.13. Company accelerating new store openings one year ahead of plan.

    Recognition: Watch 37 → Watch 44Gap Medium · 10 → Medium · 22

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Semiconductors

    Applied Optoelectronics, Inc.AAOI

    8-K · Items 1.01, 1.02 — Material agreement

    AAOI acquired three Houston buildings (736,216 sq ft) for $102.25M by exercising purchase options from May 2026 leases. Leases terminated without early penalty. Transaction converts operating leases to owned real estate.

    Value: Balanced 50 → Balanced 55

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Immix Biopharma, Inc.IMMX

    8-K · Item 2.02 — Results of operations

    Immix reported 89% complete response rate in NEXICART-2 with potential 98% future rate. Strong cash position ($340.9M) extends runway to mid-2028. BLA submission planned mid-2027; NEXICART-3 initiation H1 2027. Key hires in technical operations and regulatory affairs.

    Recognition: Watch 42 → Watch 39Gap High · 33 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Semiconductors

    Axt IncAXTI

    Quarterly report (10-Q), period ending 30 Sep 2026

    Value: Weak 24 → Watch 41

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Absci CorpABSI

    8-K · Items 2.02, 8.01 — Results of operations

    Absci reported Q3 2026 results with ABS-201 HEADLINE trial on track for December interim proof-of-concept data in pattern hair loss. Announced Phase 2 endometriosis trial details (mid-2027 initiation) and appointed experienced Chief Commercial Officer. Cash runway extends to H2 2028.

    Recognition: Balanced 61 → Balanced 56Gap Medium · 18 → High · 37

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 10-QFiled 12 Nov 2026All industries

    American Integrity Insurance Group, Inc.AII

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Balanced 45 → Balanced 48Gap Low · 0 → Medium · 13

    More of the market is starting to notice.

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Accelerant HoldingsARX

    8-K · Item 2.02 — Results of operations

    Q3 2026: Exchange Written Premium grew 27% YoY to $1.33B; adjusted EBITDA $71.3M (25.4% margin); 26 new MGAs added. Pending Thoma Bravo acquisition expected to close H1 2027. GAAP net loss of $9.2M offset by adjusted net income of $38.2M.

    Recognition: Balanced 63 → Balanced 48

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Altimmune, Inc.ALT

    8-K · Item 2.02 — Results of operations

    Altimmune reports Q3 2026 results with $480M cash position. PERFORMA Phase 3 MASH trial progressing as planned; positive RECLAIM Phase 2 AUD data presented at AASLD. FDA End-of-Phase 2 meeting scheduled December 2026 for AUD program. RESTORE Phase 2 ALD enrollment complete.

    Gap High · 41 → Very high · 51

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    SpyGlass Pharma, Inc.SGP

    8-K · Items 2.02, 8.01 — Results of operations

    SpyGlass Pharma completed first implantations of BIM-DRS (next-generation drug delivery system), announced four-year efficacy data for lead BIM-IOL System (37% IOP reduction, 86% off drops), acquired IOL manufacturer AVS for $13M, and maintains $215.8M cash runway through 2028.

    Gap Medium · 21 → High · 41

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Kardigan, Inc.KARD

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Low · 0 → Medium · 21

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Eastman Chemical CoEMN

    8-K · Items 1.01, 8.01 — Material agreement

    Eastman Chemical issued $300M of 5.500% notes due 2030 in a public offering. Net proceeds of ~$297.7M will be used for general corporate purposes including working capital, capex, and debt repayment.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kodiak Sciences Inc.KOD

    8-K · Item 2.02 — Results of operations

    Kodiak reported positive Phase 3 results for two lead programs (Zenkuda and tabirafusp-ted) in wet AMD, with Zenkuda meeting primary endpoint and 54% of patients achieving 6-month dosing. BLA submissions planned for Q4 2026 and Q2 2027. KSI-101 pivotal data expected December 2026.

    Gap Low · 5 → Medium · 12

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Suburban Propane Partners LpSPH

    8-K · Item 2.02 — Results of operations

    SPH reported FY2026 net income of $109.0M ($1.63/unit) and Adjusted EBITDA growth of 2.2% to $284.0M. Strong propane demand, RNG capacity expansion, debt reduction, and 7.7% distribution increase announced.

    Value: Strong 66 → Strong 69Gap Low · 7 → Medium · 22

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Industrials

    Astronics CorpATRO

    Quarterly report (10-Q), period ending 3 Oct 2026

    Recognition: Balanced 54 → Balanced 51Value: Watch 31 → Watch 35Gap Medium · 16 → High · 29

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    WEX Inc.WEX

    8-K · Items 1.01, 2.03 — Material agreement

    WEX amended its credit agreement, extending maturity to November 2031, increasing revolving facility to $1.7B and term loan to $900M, with repriced interest margins tied to leverage ratios.

    Gap Low · 5 → High · 27

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 12 Nov 2026All industries

    DPC Holdings PLCDPC

    Quarterly report (10-Q), period ending 27 Sep 2026

    Gap Very high · 58 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    DPC Holdings PLCDPC

    8-K · Item 2.02 — Results of operations

    Gap Very high · 58 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Anaptysbio, IncANAB

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 28 → High · 39

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026All industries

    Corteva, Inc.CTVA

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Very strong 80 → Strong 73

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    EDGEWELL PERSONAL CARE CoEPC

    8-K · Item 2.02 — Results of operations

    EPC reported Q4 FY2026 organic sales growth of 3.1% and adjusted EPS of $0.78 (+50% YoY). Full-year adjusted EPS of $1.93 (+6.6% YoY) met guidance. FY2027 outlook projects organic sales growth of 1.0–3.0% and adjusted EPS of $1.85–$2.15.

    Gap Medium · 20 → High · 28

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Intellia Therapeutics, Inc.NTLA

    8-K · Item 2.02 — Results of operations

    Intellia hosted investor webcast on lonvo-z (CRISPR therapy for HAE). BLA accepted by FDA with priority review; PDUFA goal date March 10, 2027. Phase 3 HAELO trial achieved primary endpoint (62% attack-rate reduction) and key secondary endpoints with favorable safety. No advisory committee planned.

    Gap Very high · 64 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Arrowhead Pharmaceuticals, Inc.ARWR

    8-K · Item 2.02 — Results of operations

    ARWR reported FY2026 results with REDEMPLO commercial momentum (63% QoQ prescription growth, 950 cumulative prescriptions), FDA STAR program entry for plozasiran sHTG indication, successful Phase 3 data, and refinanced debt at lower rates with improved terms.

    Gap Very high · 82 → Very high · 86

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Biotech

    SpyGlass Pharma, Inc.SGP

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Medium · 21 → High · 41

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 10-QFiled 12 Nov 2026All industries

    Tamboran Resources CorpTBN

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Weak 22 → Weak 16

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Industrials

    Ondas Inc.ONDS

    Quarterly report (10-Q), period ending 30 Sep 2026

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Hagerty, Inc.HGTY

    8-K · Items 1.01, 8.01 — Material agreement

    Hagerty Holding Corp. completed a secondary offering of 10M shares at $14.85/share, with a 30-day overallotment option for 1.5M additional shares. Hagerty receives no proceeds; net proceeds fund a trust redemption.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Candel Therapeutics, Inc.CADL

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 43 → Watch 36Value: Balanced 57 → Watch 36Gap High · 42 → Very high · 56

    Market attention has faded.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Enovix CorpENVX

    8-K · Item 2.02 — Results of operations

    Enovix reported Q3 2026 revenue of $11.0M (+38% YoY), record non-GAAP gross margin of 34.5%, and issued FY2027 guidance of $65–85M revenue (+75% to +128% YoY). Drone/defense pipeline grew 18% to $216M. Company restructured, retired $128M of 2030 Notes at 36% discount, and reduced annual costs by $8.5M.

    Gap High · 32 → High · 41

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Erasca, Inc.ERAS

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap Medium · 15 → Medium · 22

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Tetra Tech IncTTEK

    8-K · Items 2.02, 8.01 — Results of operations

    Tetra Tech reported record Q4 and FY2026 EPS, 13% YoY backlog growth to $4.67B, 90bps EBITDA margin expansion, and an 11% dividend increase—the 46th consecutive double-digit increase. Strong government contract wins totaling $1.9B support confidence in FY2027 guidance.

    Gap Low · 7 → High · 27

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    MeiraGTx Holdings plcMGTX

    8-K · Item 2.02 — Results of operations

    MeiraGTx reported Q3 2026 results with major regulatory milestones: MAA submission for bota-vec (XLRP) expected December 2026, BLA submission Q1 2027. Strong cash position ($184.7M) supports operations into H2 2028. Multiple clinical programs advancing; Lilly partnership generates revenue and milestone potential.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    United States Antimony CorpUAMY

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue up 16% YoY to $10.1M; gross profit surged 113% to $4.3M with margin expanding to 42%. Antimony pounds sold jumped 68% driven by DLA contract acceptance of 162k pounds. October DLA shipments added $3.6M revenue. Zeolite revenue grew 55% YoY.

    Gap Very high · 67 → Very high · 72

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Astec Industries IncASTE

    8-K · Item 1.01 — Material agreement

    Astec agreed to sell Roadtec and Carlson businesses to Komatsu for $75M enterprise value. Sale eliminates operating losses, expected to improve adjusted EBITDA margin ~200 bps and be accretive to EPS. Closes Q1 2027.

    Gap Low · 3 → Very high · 45

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Anteris Technologies Global Corp.AVR

    8-K · Item 2.02 — Results of operations

    Anteris reported Q3 2026 progress on PARADIGM Trial enrollment across multiple countries, assumed occupancy of Minnesota manufacturing facility for production scaling, and appointed new CFO. Operating cash outflow was $22.9M.

    Gap Very high · 58 → Very high · 67

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Tamboran Resources CorpTBN

    8-K · Item 2.02 — Results of operations

    Tamboran achieved first gas sales from Beetaloo Basin in September 2026, delivering 40 TJ/d to NT Government under fixed-price contract. Well performance confirms deliverability expectations with IP30 rates of 8.8–10.2 MMcf/d. Infrastructure completed on budget; ~US$180M pro forma cash balance.

    Recognition: Weak 22 → Weak 16

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 10-QFiled 12 Nov 2026Biotech

    Crescent Biopharma, Inc.CBIO

    Quarterly report (10-Q), period ending 30 Sep 2026

    Recognition: Watch 33 → Watch 30Gap Very high · 77 → Very high · 83

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Silence Therapeutics plcSLN

    8-K · Item 2.02 — Results of operations

    Silence Therapeutics announced acquisition by Merck KGaA (expected Q1 2027), reported positive Phase 2 SANRECO divesiran results with best-in-class dosing profile, and strengthened cash position to $247.7M via capital raise. Q3 operating losses improved significantly YoY.

    Gap Low · 0 → Low · 4

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    TMC the metals Co Inc.TMC

    8-K · Item 2.02 — Results of operations

    NOAA delayed final certification decision to mid-December 2026 (from end-October) due to 1,600 public comments, with no identified application deficiencies. TMC and Allseas advancing capital-light phased production approach. U.S. government funding discussions ongoing for Brownsville processing facility.

    Gap Very high · 53 → Very high · 61

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    4D Molecular Therapeutics, Inc.FDMT

    8-K · Item 2.02 — Results of operations

    4DMT completed enrollment and randomization of 4FRONT-2 Phase 3 trial for 4D-150 in wet AMD; initiated 4SIGHT Phase 3 in DME; presented positive 2-year data; hired Chief Regulatory Officer. Topline data expected Q2 2027 and H2 2027.

    Gap Very high · 46 → Very high · 54

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Prime Medicine, Inc.PRME

    8-K · Item 1.01 — Material agreement

    Prime Medicine completed an underwritten public offering of ~35.7M shares at $3.50/share, raising ~$134.7M net proceeds. Funds will support Wilson disease and alpha-1 antitrypsin deficiency programs, R&D, and general corporate purposes.

    Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Software / SaaS

    NIQ Global Intelligence plcNIQ

    8-K · Items 2.02, 8.01 — Results of operations

    NIQ exceeded guidance for 6th consecutive quarter with positive GAAP EPS ($0.12/share) for first time since IPO. Achieved 2.9x net leverage one quarter ahead of plan. Board authorized $150M share repurchase program.

    Recognition: Balanced 60 → Balanced 57Gap Low · 0 → Medium · 22

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.